739342-23-5

Basic information

• Product Name: 3-(benzyloxy)-2-ethyl-1-(4-hydroxybutyl)pyridin-4(1H)-one
• Synonyms: 3-(benzyloxy)-2-ethyl-1-(4-hydroxybutyl)pyridin-4(1H)-one
• CAS NO: 739342-23-5
• Molecular Weight: 301.386
• Mol File: 739342-23-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(benzyloxy)-2-ethyl-1-(4-hydroxybutyl)pyridin-4(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(benzyloxy)-2-ethyl-1-(4-hydroxybutyl)pyridin-4(1H)-one(739342-23-5)
• EPA Substance Registry System: 3-(benzyloxy)-2-ethyl-1-(4-hydroxybutyl)pyridin-4(1H)-one(739342-23-5)

Safety Data

• Hazardous Substances Data: 739342-23-5(Hazardous Substances Data)

Upstream product

• 13325-10-5 4-Aminobutanol 
• 111782-87-7 3-(benzyloxy)-2-ethyl-4H-pyran-4-one 
• 4940-11-8 2-ethyl-3-hydroxy-4-pyranone 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 

Relevant articles and documents

5-aminolevulinic acid/3-hydroxyl pyridone conjugate, preparation method therefor and use of 5-aminolevulinic acid/3-hydroxyl pyridone conjugate

The invention discloses conjugates of 5-aminolevulinic acid and 3-hydroxyl pyrid-4-one. The conjugates are conjugates of 5-aminolevulinic acid and an iron chelating agent, i.e., 3-hydroxyl pyrid-4-one and are ALA-HPO conjugates 1 to 4 separately. The invention further simultaneously discloses a preparation method for the conjugates of 5-aminolevulinic acid and 3-hydroxyl pyrid-4-one and use of the conjugates of 5-aminolevulinic acid and 3-hydroxyl pyrid-4-one. The conjugates can be used for preparing photodynamic therapy drugs and can also be used for preparing drugs for treating skin cancer, lung cancer or verruca acuminata.

Synthesis, physicochemical properties, and evaluation of N-substituted- 2-alkyl-3-hydroxy-4(1H)-pyridinones

The synthesis of a range of 3-hydroxy-4(1H)-pyridinones with potential for the chelation of iron(III) is described. The pK(a) values of respective ligands and the stability constants of their iron(III) complexes are presented. The distribution coefficient values of a range of 48 hydroxypyridinones and their corresponding iron(III) complexes between 1- octanol and MOPS buffer (pH 7.4) are reported. The range of log D(complex) values covers 7 orders of magnitude. The results suggest the existence of a biphasic relationship between the distribution coefficient values of the chelator and the corresponding iron(III) complexes. For ligands with a log D(ligand) = -1, a linear relationship exists with a value of the slope 2.53, whereas with ligands with a log D(ligand) 59Fe]ferritin-loaded rat model. Both systems compare the ability of chelators to remove iron from the liver, the prime target organ in thalassemia. The N-(hydroxyalkyl)-3-hydroxypyridin-4-ones are demonstrated to be orally active under the in vivo conditions adopted. Thus both 1- (hydroxyalkyl)- and 1-(carboxyalkyl)pyridinones are able to remove iron from the liver. Although 1-(carboxyalkyl)hydroxypyridinones are: active, they do not demonstrate any clear advantage over Deferiprone (1,2-dimethyl-3- hydroxypyridin-4-one). Indeed 1-(hydroxyalkyl)hydroxypyridinones which are known to be rapidly converted to 1-(carboxYalkyl)hydroxypyridinones are also marginally superior to Deferiprone. In contrast, 2-ethyl-1-(2'- hydroxyethyl)3-hydroxypyridin-4-one, which is not metabolized to the corresponding (carboxyalkyl)hydroxypyridinone, was found to be superior to Deferiprone and therefore deserves further consideration as an orally active iron chelator with potential for the treatment of iron overload associated with transfusion-dependent thalassemia.